Balyasny Asset Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Balyasny Asset Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-23,106	Closed	-$124K	–	3223
2024 Q1	$124K	Buy	+23,106	New	+$160K	﹤0.01%	2480
2022 Q3	–	Sell	-1,483	Closed	-$14K	–	3337
2022 Q2	$14K	Buy	+1,483	New	+$13.9K	﹤0.01%	2533
2018 Q2	–	Sell	-1,030	Closed	-$134K	–	2215
2018 Q1	$134K	Sell	1,030 -1,900	-65%	-$208K	﹤0.01%	1806
2017 Q4	$285K	Buy	+2,930	New	+$394K	﹤0.01%	1767

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Balyasny Asset Management's SYRS Position: Q2 2024 in Review

Balyasny Asset Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2024, closing a stake of 23,106 shares — an estimated $124K sold.

Balyasny Asset Management first reported a position in SYRS in Q4 2017 and held it in 4 quarters. The position peaked at $285K in Q4 2017. 70 funds tracked by Wall St. Rank hold SYRS as of Q2 2024.

Balyasny Asset Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Balyasny Asset Management sold 23,106 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $124K.
Balyasny Asset Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 4 quarters.
Balyasny Asset Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $285K in Q4 2017.
70 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.